glp-1 research chemical incretin peptide - metabolic studies Semaglutide 5mg for Research |

Purpose-built for physicians GLP-1s may reduce cardiovascular risk in rheumatoid arthritis treated with JAK inhibitors GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors, according to data presented at the EULAR 2025 Congress

These findings suggest that GLP-1RAs may have therapeutic potential beyond diabetes and obesity, particularly in the treatment of addictions to palatable foods, alcohol, and drugs

By stopping this, the MASLD may be prevented or alleviated if it already exists

I even give subscriptions to family members because I believe in what Consumer Lab does

This whole-person approach can help stall or soften the impacts of the hormonal cascade

On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile